MPP-Our Work

The Medicines Patent Pool (MPP) is a public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries, especially for HIV, hepatitis C and tuberculosis treatment. To date, we have secured licences for thirteen antiretrovirals, three hepatitis C direct-acting antivirals, one tuberculosis medicine and an HIV technology platform.

We have sublicensed to many product developers and generic manufacturers to develop and supply medicines in developing countries. Access our “Products licensed” page.

MPP in Numbers

10 patent holders with MPP signed agreements

26 million patient-years through MPP’s generic partners from January 2012 to June 2019

22 generic manufacturers and product developers sublicensed from the MPP

18 products licensed to the MPP

150+

150+ ongoing pharmaceutical development projects

87% to 91%

87% to 91% of people living with HIV in developing countries covered by the MPP adult licences

92 to 131

92 to 131 countries covered by MPP adults licences

1.23

1.23 billion dollars saved, from January 2012 to June 2019

KPMG calculated savings of USD1.23 billion and supply of 26 million patient-years of treatments through MPP’s generic partners from January 2012 to June 2019. Read the KPMG report.
An impact analysis, highlighting MPP’s sublicensees’ progress on dolutegravir (DTG)-based regimens from 2017 to June 2019 is also available HERE
MPP-WHO forecasting collaboration: MPP and the World Health Organization (WHO) prepare joint forecasts on the use of antiretroviral medicines in developing countries. We work together to pool respective information and insights from our partners. Read our latest forecast analysis : Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025